TITLE

SHORT CUTS

AUTHOR(S)
Fister, Kristina
PUB. DATE
September 2009
SOURCE
BMJ: British Medical Journal (Overseas & Retired Doctors Edition;9/5/2009, Vol. 339 Issue 7720, p536
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This section discusses various health-related studies published in different journals. A study published in the "New England Journal of Medicine" estimated the cumulative doses of radiation received by patients in the U.S. during imaging procedures. Another study published in the same journal determined the cardiac troponin concentrations in 718 consecutive patients with suspected myocardial infarction. Meanwhile, a research published in the "Journal of the American Medical Association" discovered that clopidogrel is not the best antiplatelet drug for patients with cytochrome P450 (CYP) 2C19*2 variant.
ACCESSION #
44208484

 

Related Articles

  • Prasugrel Versus High Dose Clopidogrel to Overcome Early High on Clopidogrel Platelet Reactivity in Patients with ST Elevation Myocardial Infarction. Alexopoulos, D.; Theodoropoulos, K.; Stavrou, E.; Xanthopoulou, I.; Kassimis, G.; Tsigkas, G.; Damelou, A.; Davlouros, P.; Hahalis, G.; Athanassiadou, A. // Cardiovascular Drugs & Therapy;Oct2012, Vol. 26 Issue 5, p393 

    Objective: There is a paucity of data regarding the early effectiveness of the proposed 600 mg clopidogrel loading dose (LD) on platelet reactivity (PR) in ST elevation myocardial infarction (STEMI) patients. If high on-treatment platelet reactivity (HTPR) is present, prasugrel reloading and...

  • Progress of Antiplatelet Pharmacogenomics. Oestreich, Julie H. // Current Drug Targets;Nov2011, Vol. 12 Issue 12, p1848 

    Numerous genetic variants have been studied in the context of antiplatelet responsiveness, particularly for aspirin and clopidogrel. The majority of these variants have failed to demonstrate any measurable level of clinical validity with the exception of the CYP2C19*2 allele. Several studies...

  • Effect of CYP2C19 variants on clopidogrel.  // Clinical Cardiology Alert;Nov2009 Clinical Briefs, p21 

    The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome...

  • Effect of CYP2C19 variants on clopidogrel. Kuritzky, Louis // Primary Care Reports;Nov2009 Primary Care, p21 

    The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome...

  • Effect of CYP2C19 variants on clopidogrel.  // Clinical Oncology Alert;Nov2009 Supplement, p21 

    The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome...

  • Effect of CYP2C19 variants on clopidogrel. Kuritzky, Louis // Neurology Alert;Nov2009 Primary Care, p21 

    The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome...

  • Antiplatelet Effect of Clopidogrel Can Be Reduced by Calcium-Channel Blockers. Kwon-Duk Seo; Young Dae Kim; Young-Won Yoon; Jong-Youn Kim; Kyung-Yul Lee // Yonsei Medical Journal;May2014, Vol. 55 Issue 3, p683 

    Purpose: Clopidogrel is metabolized by the hepatic cytochrome P450 (CYP) system into its active thiol metabolite. CYP3A4 is involved in the metabolism of both clopidogrel and dihydropyridine calcium channel blockers (CCBs). A few reports have suggested an inhibitory interaction between CCBs and...

  • Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update. Scott, S A; Sangkuhl, K; Stein, C M; Hulot, J‐S; Mega, J L; Roden, D M; Klein, T E; Sabatine, M S; Johnson, J A; Shuldiner, A R // Clinical Pharmacology & Therapeutics;Sep2013, Vol. 94 Issue 3, p317 

    Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss-of-function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss-of-function alleles confer increased risks for serious...

  • Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. Bo Jin; Huan-Chun Ni; Wei Shen; Jian Li; Hai-Ming Shi; Yong Li // Molecular Biology Reports;Mar2011, Vol. 38 Issue 3, p1697 

    Patients with lesser degrees of platelet inhibition in response to clopidogrel appear to be at increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have been proposed as possible mechanisms for nonresponsiveness to clopidogrel. Published data on the association...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics